文献速递白血病MDS 与骨髓增殖性肿瘤

慢性粒单核细胞白血病中合成致死靶向ERCC1和CDKN1A的转录组学依据

Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
PubMed 文献 · Br J Haematol · 2018-05-24

该研究通过对27例慢性粒单核细胞白血病(CMML)患者和9例对照的骨髓进行增强RNA测序筛选DNA修复基因,并在74例CMML患者独立队列及70例骨髓增生异常综合征、66例急性髓系白血病和25例慢性髓性白血病病例中验证。发现BAP1和PARP1下调为CMML特异,CDKN1A和ERCC1过表达与化疗难治相关,SRSF2突变者DNA修复基因存在大量异常剪接。

要点

  • BAP1和PARP1下调为CMML与其他相关疾病相比的特异性表现。
  • CDKN1A和ERCC1过表达不依赖启动子甲基化,且与化疗难治相关。
  • SRSF2突变患者DNA修复基因存在大量异常剪接,单链断裂通路占数量优势。

核心结论

  • 结果突出了CMML中潜在的治疗靶点,该病目前治疗选择很少。

研究设计与样本

  • 发现队列对27例CMML患者和9例对照的骨髓进行增强RNA测序筛选DNA修复基因。
  • 在CMML CD34+骨髓选定细胞和74例CMML患者独立队列中验证4个差异表达候选基因,并通过靶向测序进行突变背景分析。
  • 在70例骨髓增生异常综合征、66例急性髓系白血病和25例慢性髓性白血病病例中评估候选基因的转录行为。

主要发现

  • BAP1和PARP1下调为CMML与其他相关疾病相比的特异性表现。
  • 染色质调节因子突变病例显示BAP1剂量降低。
  • 双链断裂忠实性基因CDKN1A和ERCC1显著过表达,不依赖启动子甲基化,且与化疗难治相关。
  • 携带剪接组分SRSF2突变的患者DNA修复基因存在大量异常剪接事件,单链断裂通路在数量上占优势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the absence of mutations in the DNA repair machinery in myeloid malignancies, the advent of high-throughput sequencing and discovery of splicing and epigenetics defects in chronic myelomonocytic leukaemia (CMML) prompted us to revisit a pathogenic role for genes involved in DNA damage response. We screened for misregulated DNA repair genes by enhanced RNA-sequencing on bone marrow from a discovery cohort of 27 CMML patients and 9 controls. We validated 4 differentially expressed candidates in CMML CD34+ bone marrow selected cells and in an independent cohort of 74 CMML patients, mutationally contextualized by targeted sequencing, and assessed their transcriptional behavior in 70 myelodysplastic syndrome, 66 acute myeloid leukaemia and 25 chronic myeloid leukaemia cases. We found BAP1 and PARP1 down-regulation to be specific to CMML compared with other related disorders. Chromatin-regulator mutated cases showed decreased BAP1 dosage. We validated a significant over-expression of the double strand break-fidelity genes CDKN1A and ERCC1, independent of promoter methylation and associated with chemorefractoriness. In addition, patients bearing mutations in the splicing component SRSF2 displayed numerous aberrant splicing events in DNA repair genes, with a quantitative predominance in the single strand break pathway. Our results highlight potential targets in this disease, which currently has few therapeutic options.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hurtado AM, Luengo-Gil G, Chen-Liang TH, et al. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. Br J Haematol. 2018. PMID: 29797327. doi:10.1111/bjh.15408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。